Close Menu

SBIR grant

The products will initially be commercialized for research applications, but the firm hopes to move into diagnostics down the road.

The two-year grant is worth $350,000 in its first year.

The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.

The grant project is part of the company's ongoing effort to expand into pre-designed research tests for disease biomarkers and point-of-care diagnostics.

The company is using a $3 million, three-year grant to clinically validate the test, which it hopes will be the first of its kind approved by the FDA.

The company has previously published data showing the miRNA expression in plasma could identify patients with mild cognitive impairment with 96 percent accuracy.

The fully automated self-confirming assay will simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen.

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics today announced it has been awarded a two-year $1.4 million grant from the National Cancer Institute to develop and validate a diagnostic test for differentiating various B-cell non-Hodgkin lymphomas from benign lymphoproliferative diseases.

NEW YORK (GenomeWeb) – Mediomics has received a $970,000 Small Business Innovation Research grant from the National Cancer Institute to develop a panel of single-chain variable fragments to detect modified proteins, the company said Friday.

NEW YORK (GenomeWeb) — Bay Area startup Diassess has been awarded nearly $300,000 from the National Institutes of Health for the first year of a two-year project to develop a point-of-care, nucleic acid amplification-based diagnostic device for sexually transmitted infections, with an initial foc

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.